Logo

ActivX, Following Acquisition, Becomes Subsidiary of Kyorin Pharmaceutical

Feb 02, 2005

NEW YORK, Feb. 2 (GenomeWeb News) - Kyorin Pharmaceutical of Tokyohas completed its acquisition of ActivX Biosciences, La Jolla, Calif.-based ActivX said today.

 

ActivX became a wholly owned subsidiary of Kyorin, serving as the company's USdrug-discovery and development center.

 

The $21 million acquisition was first announced in December.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.